OverviewShare July 31, 2026 Dr. Olivia Fankuchen discusses the role of Dato-DXd (Datroway) as a second-line treatment option in high-risk EGFR-mutant NSCLC, including its use in MET-driven resistance and combination with chemotherapy on the Conference floor of ILCC 2026. Share Share Share Related Posts EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar July 31, 2026 Tags:2L Treatment StrategiesADCAmivantamabChemotherapyCombination TherapyDato-DXdDatrowayFLAURA2High-Risk DiseaseILCCMETOsimertinibResistanceRybrevantTagrissoTreatment SelectionVideo
EGFR Channel News Network: On Location at ILCC 2026 with Dr. Deborah Doroshow and Dr. Amin Nassar July 31, 2026
